The US Food and Drug Administration (FDA) has approved the Gore Cardioform septal occluder for closure of patent foramen ovale (PFO) to prevent recurrent ischemic stroke, the manufacturer, WL Gore & ...

FLAGSTAFF, Ariz.- W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration's (FDA's) premarket approval (PMA) of the GORE® CARDIOFORM ASD Occluder for the percutaneous closure of ...

Global PFO Closure Device Market Size was estimated at USD 121.53 million in 2021 and is projected to reach USD 208.00 million by 2028, exhibiting a CAGR of 7.98% during the forecast period. “PFO ...

TCT 195: Percutaneous Patent Foramen Ovale Closure for Migraine with the Amplatzer PFO Occluder: A Pooled Analysis of Individual Participant Data from the Randomized Trials Receive the the latest news ...

Rochester, MN - A case report of a patient who suffered erosion of an Amplatzer septal-occluder device (St Jude Medical) six years after it was implanted, resulting in cardiac tamponade and ...

W.L. Gore & Associates (Gore) has launched a multicenter, prospective, randomized placebo- and sham-controlled investigational study that will evaluate the safety and efficacy of transcatheter closure ...

FLAGSTAFF, Ariz., June 4, 2019 /PRNewswire/ -- W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration's (FDA's) premarket approval (PMA) of the GORE® CARDIOFORM ASD Occluder ...

Because the benefits of patent foramen ovale closure were once in question, physicians remain hesitant about its use in clinical practice. Recent data, however, have confirmed the safety and efficacy ...

Over the past years, many researchers have been engaged in deciphering the interrelationship between migraine and patent foramen ovale (PFO) and have tried to answer the question of whether PFO ...

Please provide your email address to receive an email when new articles are posted on . Younger patients with a patent foramen ovale who have had a cryptogenic ischemic stroke should undergo PFO ...